financetom
Business
financetom
/
Business
/
Gladstone Commercial Q3 revenue beats estimates on strong rent collection
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gladstone Commercial Q3 revenue beats estimates on strong rent collection
Nov 3, 2025 1:24 PM

Overview

* Gladstone Q3 operating revenue grows 3.3%, beating analyst expectations

* Net income for Q3 beats analyst estimates despite decline from prior quarter

* Company acquired six-facility portfolio and sold non-core property

Outlook

* Gladstone Commercial ( GOOD ) did not provide specific future guidance in the statement

Result Drivers

* PROPERTY ACQUISITIONS - Co acquired a six-facility portfolio, contributing to increased operating revenue

* RENT COLLECTION - Co collected 100% of cash rents due during Q3

* CAPITAL RECYCLING - Sale of non-core property aligns with capital recycling strategy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $40.84 $40.10

Operatin mln mln (4

g Analysts

Revenue )

Q3 Net Beat $4.13 $4.07

Income mln mln (4

Analysts

)

Q3 -$26.02

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the diversified reits peer group is "buy"

* Wall Street's median 12-month price target for Gladstone Commercial Corp ( GOOD ) is $14.50, about 21.2% above its October 31 closing price of $11.43

* The stock recently traded at 50 times the next 12-month earnings vs. a P/E of 48 three months ago

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Constellation Brands Slashes Fiscal 2026 Comparable Earnings Outlook
Constellation Brands Slashes Fiscal 2026 Comparable Earnings Outlook
Sep 2, 2025
07:59 AM EDT, 09/02/2025 (MT Newswires) -- Constellation Brands ( STZ ) said Tuesday that it is lowering its fiscal 2026 comparable earnings outlook to a range of $11.30 to $11.60 per share, compared with $12.60 to $12.90 previously. Analysts surveyed by FactSet expect $12.64. Chief Executive Bill Newlands cited dampened demand and more volatile consumer purchasing behavior amid a...
Lifezone Metals Closes $60 Million Bridge Loan From Taurus Mining
Lifezone Metals Closes $60 Million Bridge Loan From Taurus Mining
Sep 2, 2025
08:03 AM EDT, 09/02/2025 (MT Newswires) -- Lifezone Metals ( LZM ) said Tuesday its wholly-owned subsidiary, Kabanga Nickel has closed the $60 million bridge loan facility agreement with Taurus Mining Finance Fund. The company further added that it has received the first tranche of $20 million under the bridge loan from Taurus and the future tranches may be disbursed...
Market Chatter: Amazon US Prime Sign-Ups Fall Short of Last Year Tally, Company Target
Market Chatter: Amazon US Prime Sign-Ups Fall Short of Last Year Tally, Company Target
Sep 2, 2025
08:00 AM EDT, 09/02/2025 (MT Newswires) -- Amazon.com's ( AMZN ) US Prime sign-ups fell short of last year's aggregate and the company's own targets, Reuters reported Tuesday, citing internal data. The e-commerce giant registered 5.4 million US sign-ups over the 21-day run-up to Prime Day and its four-day sales event from July 8 through July 11, according to the...
Stoke Therapeutics, Biogen Say Studies Support Potential of Dravet Syndrome Treatment
Stoke Therapeutics, Biogen Say Studies Support Potential of Dravet Syndrome Treatment
Sep 2, 2025
08:00 AM EDT, 09/02/2025 (MT Newswires) -- Stoke Therapeutics ( STOK ) and Biogen (BIIB) said Tuesday that data from the phase 1/2a and open-label extension studies of zorevunersen supported the potential of the investigational drug to treat Dravet syndrome. Across the studies, the drug showed substantial and durable reductions in major motor seizure frequency and continuing improvements in cognition,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved